Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Ferenci, P; Stauber, R; Steindl-Munda, P; Gschwantler, M; Fickert, P; Datz, C; Müller, C; Hackl, F; Rainer, W; Watkins-Riedel, T; Lin, W; Krejs, GJ; Gangl, A; Austrian Hepatitis Study Group.
Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Austrian Hepatitis Study Group.
Eur J Gastroenterol Hepatol. 2001; 13(6):699-705
Doi: 10.1097/00042737-200106000-00014
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Fickert Peter
- Krejs Günter Josef
- Stauber Rudolf
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Objective To investigate the efficacy of high-dose interferon alpha (IFN-a) with or without ribavirin in interferon (IFN) non-responders. Study design 304 chronic hepatitis C patients received 5 MU IFN-alpha 2b (IntronA(R), Schering-Plough, Kenilworth, NJ, USA) three times a week for 3 months. Non-responders were randomized either to continue with IFN (IFN 5 MU/TIW followed by 10 MU/TIW, each for 3 months) alone (group A: n = 76, m:f = 54:22, age 45.7 +/- 12 years, 16% cirrhosis, alanine aminotransferase [ALT] 66 +/- 35 U/I) or in combination with ribavirin (similar to 14 mg/kg/day) (group B: n = 81, m:f = 57 :24, age 48.2 +/- 12 years, 17% cirrhosis, ALT 71 +/- 40 U/I), At the end of treatment, patients were followed for 6 months. Main outcome measures Virological response at end of treatment and 6 months thereafter. Setting University hospitals and tertiary referral centres. Results At the end of treatment, eight (10.8%) and 25 (31.3%, P= 0.0066) patients were HCV-RNA negative, and 51 and 39 were HCV-RNA positive, in groups A and B, respectively. There were 17 drop-outs in each group. Six months after treatment, only one patient in group A (1.3%) and seven patients (8.6%, P= 0.06) in group B had normal ALT and undetectable serum HCV-RNA. Conclusions A combination of high-dose IFN with ribavirin induces a short-lasting complete response in about one-third of IFN-non-responders. Eur J Gastroenterol Hepatol 13:699-705 (C) 2001 Lippincott Williams & Wilkins.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Antiviral Agents - administration and dosage
- Base Sequence -
- Dose-Response Relationship, Drug -
- Drug Therapy, Combination -
- Female -
- Follow-Up Studies -
- Hepatitis C, Chronic - diagnosis Hepatitis C, Chronic - drug therapy
- Humans -
- Interferon-alpha - administration and dosage
- Interferons - administration and dosage
- Male -
- Middle Aged -
- Molecular Sequence Data -
- Organization and Administration -
- Polymerase Chain Reaction -
- Probability -
- Prospective Studies -
- RNA, Viral - analysis
- Reference Values -
- Ribavirin - administration and dosage
- Treatment Failure -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- chronic hepatitis C
- interferon
- randomized trial
- ribavirin